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Abstract: 
Coccidioidomycosis is usually acquired by inhalation of spores of Coccidioides immitis and C. 
posadasii.   The disease ranges from a self-limited acute pneumonia (Valley Fever) to a 
disseminated disease.  We present a 44 year-old healthy male who had patchy hair loss of several 
months duration resembling discoid lupus.  He developed a firm non-scaly red plaque on the 
right forehead.  Initial biopsy showed spongiotic dermatitis, and he was treated with systemic 
steroids.  He then developed forehead and periorbital cellulitis and was treated with systemic 
antibiotics.  A second biopsy showed fungal hyphae and he was treated with itraconazole 200 mg 
bid for 4 months beyond clinical resolution.  A year later, he presented with intermittent swelling 
of the right forehead lesion and worsening of the scalp lesions. A forehead biopsy showed 
interface dermatitis and negative PAS stain for fungi. Scalp biopsy was highly suggestive of 
discoid lupus and he was started on plaquenil.  Many months later, a third biopsy showed fungal 
infection, and the culture grew C. immitis.  He was treated with itraconazole.  Retrospectively, 
the patient gave a history of Valley fever six years back when he was in Arizona. 
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Introduction: 
Coccidioidomycosis is an infection usually acquired by inhalation of spores of a dimorphic 
fungus of the genus Coccidioides (Coccidioides immitis and C. posadasii) [1].   The disease 
ranges from a self-limited acute pneumonia (Valley Fever) to dissemination in 
immunosuppressed patients.  The most common form of the disease is primary pulmonary 
coccidioidomycosis and is usually asymptomatic in 60% of patients [2,3]. Dermatologic 
manifestations may occur in 50% of cases during Valley Fever [4].  Immunity to exogenous 
reinfection occurs in most patients with primary disease [5].  Here, we present a case of 
cutaneous coccidioidomycosis reoccurring six years after the initial disease. 
Case Presentation: 
On February 7, 2012 a 44 year old male was seen at an outside clinic for a two-month history of 
hair loss and he was treated with doxycycline for presumed scalp folliculitis, resembling discoid 
lupus.  Two of the patient’s siblings had lupus erythematosus. Then, he presented to us with a 
firm non-scaly red plaque on the right forehead.  On examination, there were two atrophic 
patches of hair loss with hyperpigmented center suggestive of scarring alopecia, discoid lupus, or 
orlichen planopilaris.  He was treated with clobetasol propionate 0.05% lotion once a day. 
One week later, he presented with a firm plaque, 3x3 cm, on the right forehead with an 
associated mild swelling of the surrounding area with no scales.  The working diagnoses were 
calcinosis cutis or discoid lupus.  Antinuclear antibody (ANA) was negative. A 3-mm skin 
biopsy was taken and he was started on a tapering dose of oral prednisone.  The right forehead 
biopsy showed spongiotic dermatitis with chronic perivascular and periadnexal inflammation 
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with numerous eosinophils, suggestive of arthropod bite, drug reaction or urticarial reaction 
(Figure 1). 
Ten days later, he presented with a swelling of the right side of the face associated with purulent 
discharge of one-day duration.   He had no fever or chills.  Examination showed a mass with 
fluctuation on the forehead. Prednisone was discontinued and he was started on amoxicillin-
clavulanic acid. The following day, the swelling got worse and he was unable to open his right 
eye.  He was admitted as a case of eosinophilic cellulitis.  Vancomycin was started in addition to 
pain medications. WBC was 9,500 with 7% eosinophilia and IgE 7420.  Next day, the swelling 
markedly improved and the forehead lesion was crusting and erythematous. Culture of forehead 
lesion grew coagulase negative Staphylococcous.  He did well and was discharged on 
clindamycin. 
On follow up one week after discharge, there was a 2-cm infiltrated plaque on the right forehead 
with overlying crust.  Two biopsies were taken for hematoxylin and eosion stain and fungal, 
mycobacteria and bacterial cultures.  The patient was treated with itraconazole 200 mg bid and 
clindamycin was continued as the infectious disease physician felt that the lesion resembled 
coccidioidomycosis.   Histopathology showed fungal granulomatous inflammation (figure 2) and 
the tissue grew a mold.  However, no further characterization was done by the microbiology 
laboratory.  The patient was kept on itraconazole for a total of 4 months until clinically the 
forehead lesion resolved completely. 
In April 2013, he presented with pruritic scalp lesions, hair loss, and a mobile cystic mass on the 
right forehead. Biopsies showed interface dermatitis with a superficial, perivascular interstitial, 
and perifollicular lymphohistiocytic infiltrate extending to the deep margins suggestive of lupus 
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erythematosus. GMS stain was negative for fungal organism. ANA was negative and the patient 
was started on plaquenil 200 mg bid and tacrolimus ointment to scalp lesions.  The forehead 
lesion worsened and a repeat biopsy showed granulomatous dermatitis with fungal elements 
(figure 3) and the culture grew C.  immitis (figure 4).  The patient was started on voriconazole 
200 mg bid initially then it was changed to itraconazole after a couple of weeks for compliance 
issues.  In July 2014, Coccidioides antibodies level was 1:8 and then the patient recalled having a 
diagnosis of Valley Fever in Arizona in 2006 for which he was treated.  C. immitis titer was 
monitored and remained at 1:2 after completing 12 months of therapy.  He was seen on a regular 
follow up and the forehead lesion healed.    
DISCUSSION 
Coccidioidomycosis is usually acquired through inhalation of the spores of C. immitis or C. 
posadasii.  C. immitis is geographically found in central and southern California including the 
San Joaquin Valley whereas C. posadasii is found in Arizona, New Mexico, Texas, Nevada and 
Utah [6].  The most frequent manifestation of coccidioidomycosis is being asymptomatic or as a 
mild upper respiratory infection.  Other patients may develop an acute respiratory infection one 
to four weeks after exposure [2,3].  Extrapulmonary dissemination may occur in 22% of patients 
with racial difference where African American develop disseminated bony disease and Filipinos 
develop cutaneous or central nervous system disease [2], and predominance among 
immunocompromized patients [7]. Skin involvement presents with papules, nodules, ulcers, 
warty lesions or acne like anywhere on the body but most common on the face.  The current case 
did not raise the diagnosis of coccidioidomycosis due to the non-availability of a previous history 
and thus the diagnosis was not considered as was stated previously [8]. Later on, the history was 
obtained as a recollection of an initial diagnosis of coccidioidomycosis six years previously.  
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One of the mechanisms of recurrent disease is related to reactivation of the primary infection in 
immunocompromized patients [9].  In the present case, there was no evidence of 
immunosuppression prior to the onset of the coccidioidal recurrence and the ten-day course of 
prednisone was unlikely to cause severe immunosuppression.  Thus, the recurrence of 
coccidioidomycosis six years after primary coccidioidal pneumonia is distinctly unusual.  
Cutaneous coccidioidomycosis might be misdiagnosed as discoid lupus or atopic dermatitis [10].  
Cutaneous manifistations of coccidioidomycosis could be an immunologic reaction during an 
acute primary pulmonary infection, may present as an organism-specific manifestation as a result 
of hematogenous spread and rarely as a direct skin inoculation [11,12].  In a study of 34 patients, 
the mean time to relapse after completion of therapy was 7.3 months (range, 1-21 months) [13].  
Following antifungal therapy for primary pulmonary infection, relapses were reported up to four 
years after treatment [2,14].  However, early treatment of coccidioidal pneumonia with an oral 
antifungal such as fluconazole alters the natural history of coccidioidal infection. Thus, the 
relapse in those cases was likely related to the fact that azoles are not fungicidals and do not 
eradicate infections. This patient had relapse after a six-year period and unfortunately the details 
of his initial illness and therapy are not known.  Treatment depends on the immune status and the 
extent of the disease. Azole antifungals are given for 3-6 months and therapy is continued for an 
additional 6 months after clinical response [12,15–17].  However, therapy is often unable to 
prevent relapse [15].  The recommended duration of therapy for cutaneous disease is at least 6–
12 months [16,17]. 
In conclusion, we believe that our patient’s reactivation of cutaneous coccidioidomycosis might 
be secondary to insufficient treatment of the first episode.  The recurrence of coccidioidomycosis 
six years after primary coccidioidal pneumonia is distinctly unusual. 
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Figures Legends: 
 
 Figure 1: First biopsy demonstrating superficial spongiotic dermatitis with eosinophils 
(hematoxylin and eosin, x280 magnification) 
Figure 2: Second biopsy with fungal granulomatous inflammation with arrow pointing at 
Coccidioidomycosis endospore (hematoxylin and eosin, x880 magnification) 
 
 Figure 3: Cluster of fungal Coccidioidomycosis endospores at arrow (Grocott’s methenamine 
silver, x1100 magnification) 
Figure 4: After 36 days of incubation, a lactophenol blue stain shows a typical hyaline single-
celled rectangular to barrel shaped alternate arthroconidia (A) separated from each other by a 
disjunctor cell (B). 
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Figure 1:  First biopsy demonstrating superficial spongiotic dermatitis with eosinophils 
(hematoxylin and eosin, x885 magnification) 
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Figure 2: Second biopsy with fungal granulomatous inflammation with arrow pointing at 
Coccidioidomycosis endospore (hematoxylin and eosin, x880 magnification) 
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Figure 3:  Cluster of fungal Coccidioidomycosis endospores at arrow (Grocott’s methenamine 
 
silver, x1100 magnification) 
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Figure 4: After 36 days of incubation, a lactophenol blue stain showing a typical hyaline single celled 
rectangular to barrel shaped alternate arthroconidia (A) separated from each other by a disjunctor cell 
(B). 
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